These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34382514)

  • 1. Strategic Approaches to Target the Enzymes using Natural Compounds for the Management of Alzheimer's Disease: A Review.
    Ahmad SS; Younis K; Philippe J; Aschner M; Khan H
    CNS Neurol Disord Drug Targets; 2022; 21(7):610-620. PubMed ID: 34382514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatiotemporal activation of the C/EBPβ/δ-secretase axis regulates the pathogenesis of Alzheimer's disease.
    Wang H; Liu X; Chen S; Ye K
    Proc Natl Acad Sci U S A; 2018 Dec; 115(52):E12427-E12434. PubMed ID: 30530690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Structure and Function of α, β and γ-Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review.
    Ahmad SS; Khan S; Kamal MA; Wasi U
    CNS Neurol Disord Drug Targets; 2019; 18(9):657-667. PubMed ID: 31608840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-secretase/BACE1 promotes APP endocytosis and processing in the endosomes and on cell membrane.
    Wang M; Jing T; Wang X; Yao D
    Neurosci Lett; 2018 Oct; 685():63-67. PubMed ID: 30120949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles.
    Chu J; Li JG; Praticò D
    PLoS One; 2013; 8(8):e70991. PubMed ID: 23951061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of membrane trafficking in the processing of amyloid precursor protein and production of amyloid peptides in Alzheimer's disease.
    Tan JZA; Gleeson PA
    Biochim Biophys Acta Biomembr; 2019 Apr; 1861(4):697-712. PubMed ID: 30639513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics.
    Mouchlis VD; Melagraki G; Zacharia LC; Afantitis A
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31973122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
    Mazumder MK; Choudhury S
    Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease.
    Shinohara M; Fujioka S; Murray ME; Wojtas A; Baker M; Rovelet-Lecrux A; Rademakers R; Das P; Parisi JE; Graff-Radford NR; Petersen RC; Dickson DW; Bu G
    Brain; 2014 May; 137(Pt 5):1533-49. PubMed ID: 24625695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. γ-Secretase and its modulators: Twenty years and beyond.
    Xia W
    Neurosci Lett; 2019 May; 701():162-169. PubMed ID: 30763650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
    Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
    J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAGE mediates Aβ accumulation in a mouse model of Alzheimer's disease via modulation of β- and γ-secretase activity.
    Fang F; Yu Q; Arancio O; Chen D; Gore SS; Yan SS; Yan SF
    Hum Mol Genet; 2018 Mar; 27(6):1002-1014. PubMed ID: 29329433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease drug development based on Computer-Aided Drug Design.
    Zeng H; Wu X
    Eur J Med Chem; 2016 Oct; 121():851-863. PubMed ID: 26415837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease.
    Conway KA; Baxter EW; Felsenstein KM; Reitz AB
    Curr Pharm Des; 2003; 9(6):427-47. PubMed ID: 12570807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation and Glycosylation of Amyloid-β Protein Precursor: The Relationship to Trafficking and Cleavage in Alzheimer's Disease.
    Song XJ; Zhou HY; Sun YY; Huang HC
    J Alzheimers Dis; 2021; 84(3):937-957. PubMed ID: 34602469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roles of glycogen synthase kinase 3 in Alzheimer's disease.
    Cai Z; Zhao Y; Zhao B
    Curr Alzheimer Res; 2012 Sep; 9(7):864-79. PubMed ID: 22272620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of beta-amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds.
    Qiu W; Liu H; Liu Y; Lu X; Wang L; Hu Y; Feng F; Li Q; Sun H
    Med Res Rev; 2023 Jul; 43(4):1091-1140. PubMed ID: 36945751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.